多发性硬化患者中葡萄膜炎的发病率、患病率及对疾病病程的影响:芬戈莫德临床试验分析
结果显示189例患者有葡萄膜炎,162例为基线既往史(患病率0.59%),27例为新发事件(发病率0.1/100患者年),10例复发(患病率6.17%)。有葡萄膜炎患者首次复发时间更短(2.11 vs 8.12年,P=0.047),年化复发率更高(0.31 vs 0.21,P=0.025)。
要点
- MS患者中葡萄膜炎患病率为0.59%,发病率为0.1/100患者年。
- 有葡萄膜炎的MS患者年化复发率显著更高(0.31 vs 0.21,P=0.025)。
- 有葡萄膜炎的MS患者首次复发时间显著更短(2.11 vs 8.12年,P=0.047)。
核心结论
- 在MS患者中,葡萄膜炎与更高的MS复发活动相关。
研究设计与样本
- 根据基线葡萄膜炎病史和观察期间葡萄膜炎事件将患者分为4组:无病史无事件、有病史无事件、无病史有事件、有病史有事件。
- 核心研究期间患者接受芬戈莫德(0.5、1.25或5 mg/日)、安慰剂或肌注IFNβ-1a治疗,扩展期安慰剂或IFNβ-1a组转为芬戈莫德0.5 mg治疗。
主要发现
- 分析人群中189例患者有葡萄膜炎,其中162例有既往史(患病率0.59%)。
- 27例为新发葡萄膜炎事件(发病率0.1/100患者年),10/162例为复发事件(患病率6.17%)。
- 有葡萄膜炎患者较无葡萄膜炎患者首次复发时间显著更短(平均2.11 vs 8.12年;P=0.047)。
- 有葡萄膜炎患者年化复发率显著更高(0.31 vs 0.21;P=0.025)。
- 第120个月EDSS评分平均增加、6个月确认残疾进展比例及随访期间EDSS≥4的比例在有无葡萄膜炎患者间相似。
临床怎么用
- MS患者合并葡萄膜炎可能提示更高的疾病复发活动,临床应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the incidence and prevalence of uveitis and its effect on multiple sclerosis (MS) disease activity and outcomes in patients with MS who participated in the fingolimod clinical trial program. DESIGN: Analysis of pooled data (N = 27 528) from patients enrolled in fingolimod clinical studies and their extensions. Patients were stratified into 4 cohorts based on the history of uveitis at baseline and uveitis events during the observation period: no history and no uveitis events ("no uveitis"); history and no uveitis events ("history"); no history and uveitis events ("first event"); history and uveitis events ("recurrent event"). PARTICIPANTS: Adult patients diagnosed with relapsing or primary progressive MS. INTERVENTION: Patients received fingolimod (0.5, 1.25, or 5 mg/day), placebo, or intramuscular interferon beta-1a (IFNβ-1a IM) during the core studies; patients receiving placebo or IFNβ-1a IM were switched to fingolimod 0.5 mg therapy for study extensions. MAIN OUTCOME MEASURES: Incidence and prevalence of uveitis, and MS outcome measures, including annualized relapse rate (ARR), time to first relapse, change in Expanded Disability Status Scale (EDSS) score from baseline, and proportion of patients with 6-month confirmed disability progression. RESULTS: A total of 189 patients in the analysis population had uveitis. Of these, 162 patients had a history of uveitis (prevalence, 0.59%). Uveitis occurred as a first event in 27 patients (incidence, 0.1 per 100 patient-years) and as a recurrent event in 10 of 162 patients (prevalence, 6.17%). Patients with uveitis had a significantly shorter time to first relapse (mean, 2.11 vs. 8.12 years; P = 0.047) and a significantly higher ARR (0.31 vs. 0.21; P = 0.025) than those without uveitis. Mean increase in EDSS score at month 120 and the proportions of patients with 6-month confirmed disability progression, and with EDSS score ≥4 during follow-up, were similar in patients with uveitis compared with those without uveitis. CONCLUSIONS: This pooled analysis involving a large patient cohort showed that patients with MS and uveitis had increased MS relapse activity compared with those without uveitis.
引用
- Lim LL, Silva DG, Lo TC, et al. Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course. Ophthalmology. 2018. PMID: 30315901. doi:10.1016/j.ophtha.2018.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。